|
FR901228A
(fr)
|
1943-01-16 |
1945-07-20 |
Deutsche Edelstahlwerke Ag |
Système d'aimant à entrefer annulaire
|
|
US4851332A
(en)
|
1985-04-01 |
1989-07-25 |
Sloan-Kettering Institute For Cancer Research |
Choriocarcinoma monoclonal antibodies and antibody panels
|
|
US5869620A
(en)
|
1986-09-02 |
1999-02-09 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
GB9012995D0
(en)
|
1990-06-11 |
1990-08-01 |
Celltech Ltd |
Multivalent antigen-binding proteins
|
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
|
CA2078539C
(en)
|
1991-09-18 |
2005-08-02 |
Kenya Shitara |
Process for producing humanized chimera antibody
|
|
US5646253A
(en)
|
1994-03-08 |
1997-07-08 |
Memorial Sloan-Kettering Cancer Center |
Recombinant human anti-LK26 antibodies
|
|
CA2126967A1
(en)
|
1992-11-04 |
1994-05-11 |
Anna M. Wu |
Novel antibody construct
|
|
US5504048A
(en)
|
1993-06-02 |
1996-04-02 |
Fina Technology, Inc. |
Addition of lithium compounds to Ziegler-Natta catalysts for increased molecular weight in polyolefins
|
|
EP0679660A4
(en)
|
1993-11-16 |
2000-08-16 |
Pola Chem Ind Inc |
MONOCLONAL ANTIBODY AGAINST HUMAN TYROSINASE
|
|
US5635388A
(en)
|
1994-04-04 |
1997-06-03 |
Genentech, Inc. |
Agonist antibodies against the flk2/flt3 receptor and uses thereof
|
|
WO1995029193A2
(en)
|
1994-04-22 |
1995-11-02 |
The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services |
Melanoma antigens
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
US5786464C1
(en)
|
1994-09-19 |
2012-04-24 |
Gen Hospital Corp |
Overexpression of mammalian and viral proteins
|
|
ATE186745T1
(de)
|
1995-01-18 |
1999-12-15 |
Roche Diagnostics Gmbh |
Antikörper gegen cd30, die proteolytische spaltung und abgabe des membrangebundenen cd30 antigens verhindern
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
WO1997025068A2
(en)
|
1996-01-05 |
1997-07-17 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Mesothelin antigen and methods and kits for targeting it
|
|
DE19608769C1
(de)
|
1996-03-07 |
1997-04-10 |
Univ Eberhard Karls |
Antikörper BV10A4H2
|
|
US6114148C1
(en)
|
1996-09-20 |
2012-05-01 |
Gen Hospital Corp |
High level expression of proteins
|
|
US6365712B1
(en)
|
1996-10-25 |
2002-04-02 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Methods and compositions for inhibiting inflammation and angiogenesis comprising a mammalian CD97 α subunit
|
|
JP3614866B2
(ja)
|
1997-06-12 |
2005-01-26 |
リサーチ コーポレイション テクノロジーズ，インコーポレイティド |
人工抗体ポリペプチド
|
|
DE69833459T2
(de)
|
1997-12-01 |
2006-08-17 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antikörper, sowie fv moleküle, und immunkonjugate mit hoher bindungsaffinität für mesothelin und methoden für deren verwendung
|
|
US6183608B1
(en)
|
1998-02-05 |
2001-02-06 |
Wilbur A. Dammann |
Electrode positioning mechanism
|
|
US6803448B1
(en)
|
1998-07-22 |
2004-10-12 |
Vanderbilt University |
GBS toxin receptor
|
|
US6528481B1
(en)
|
1999-02-16 |
2003-03-04 |
The Burnam Institute |
NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods
|
|
HK1043608B
(en)
|
1999-08-17 |
2007-12-07 |
Biogen Ma Inc. |
Baff receptor (bcma), an immunoregulatory agent
|
|
WO2001023432A1
(en)
|
1999-09-30 |
2001-04-05 |
Kyowa Hakko Kogyo Co., Ltd. |
Human type complementarity determining region transplantation antibody against ganglioside gd3 and derivatives of antibody against ganglioside gd3
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
HK1052372A1
(zh)
|
2000-02-24 |
2003-09-11 |
Xcyte Therapies, Inc. |
细胞的同步刺激和富集
|
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
|
ATE510855T1
(de)
|
2000-03-06 |
2011-06-15 |
Univ Kentucky Res Found |
Verwendung eines antikörpers oder eines immunotoxins, der bzw. das selektiv an cd123 bindet zur beeinträchtigung hämatologischer krebs-vorläuferzellen
|
|
US7090843B1
(en)
|
2000-11-28 |
2006-08-15 |
Seattle Genetics, Inc. |
Recombinant anti-CD30 antibodies and uses thereof
|
|
CN1294148C
(zh)
|
2001-04-11 |
2007-01-10 |
中国科学院遗传与发育生物学研究所 |
环状单链三特异抗体
|
|
ES2732276T3
(es)
|
2001-08-23 |
2019-11-21 |
Rsr Ltd |
Regiones del epítopo de un receptor de tirotropina (TSH), usos del mismo y anticuerpos para el mismo
|
|
US7786269B2
(en)
|
2001-12-04 |
2010-08-31 |
Dana-Farber Cancer Institute, Inc. |
Antibody to latent membrane proteins and uses thereof
|
|
US7745140B2
(en)
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
US20040106904A1
(en)
|
2002-10-07 |
2004-06-03 |
Gonnelli Robert R. |
Microneedle array patch
|
|
DE50306067D1
(de)
|
2002-11-26 |
2007-02-01 |
Brahms Ag |
Nachweis von tsh-rezeptor-autoantikörpern mit affinitätsgereinigten antikörpern
|
|
WO2004087758A2
(en)
|
2003-03-26 |
2004-10-14 |
Neopharm, Inc. |
Il 13 receptor alpha 2 antibody and methods of use
|
|
CU23403A1
(es)
|
2003-04-23 |
2009-08-04 |
Centro Inmunologia Molecular |
Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
|
|
CN1833020A
(zh)
|
2003-06-27 |
2006-09-13 |
迪亚德克瑟斯公司 |
Pro104抗体组合物及其使用方法
|
|
CA2531118C
(en)
|
2003-07-01 |
2013-01-08 |
Immunomedics, Inc. |
Multivalent carriers of bi-specific antibodies
|
|
CA2534659A1
(en)
|
2003-08-05 |
2005-02-17 |
Morphotek, Inc. |
A variant cell surface molecule associated with cancer
|
|
JPWO2005035577A1
(ja)
|
2003-10-08 |
2007-11-22 |
協和醗酵工業株式会社 |
ガングリオシドｇｄ３に特異的に結合する抗体組成物
|
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
|
MXPA06008700A
(es)
|
2004-02-06 |
2007-01-19 |
Morphosys Ag |
Anticuerpos anti-cd38 humanos y usos para los mismos.
|
|
AU2005250408B2
(en)
|
2004-05-27 |
2010-09-23 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses therefor
|
|
EP1786918A4
(en)
|
2004-07-17 |
2009-02-11 |
Imclone Systems Inc |
NEW BISPECIFIC ANTIBODY TETRAVALENT
|
|
MY146381A
(en)
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
|
EP2322560B1
(en)
|
2005-03-10 |
2013-09-04 |
Morphotek, Inc. |
Anti-mesothelin antibodies
|
|
EP1726650A1
(en)
|
2005-05-27 |
2006-11-29 |
Universitätsklinikum Freiburg |
Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
|
|
BRPI0611800A2
(pt)
|
2005-06-15 |
2008-12-09 |
Schering Corp |
formulaÇço estÁvel de anticorpo
|
|
EP1940773B1
(en)
|
2005-08-10 |
2015-03-18 |
Johns Hopkins University |
Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors
|
|
KR20140053410A
(ko)
|
2005-08-19 |
2014-05-07 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
EA017491B1
(ru)
|
2005-12-08 |
2012-12-28 |
Медарекс, Инк. |
Человеческие моноклональные антитела к фукозил-gm1 и способы применения антифукозил-gm1 антител
|
|
EP1806365A1
(en)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
|
|
ATE509033T1
(de)
|
2006-03-20 |
2011-05-15 |
Univ California |
Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
|
|
US8603466B2
(en)
|
2006-03-29 |
2013-12-10 |
King's College London |
Agonist antibodies against TSHR
|
|
TWI395754B
(zh)
|
2006-04-24 |
2013-05-11 |
Amgen Inc |
人類化之ｃ-ｋｉｔ抗體
|
|
JP2010505775A
(ja)
|
2006-10-04 |
2010-02-25 |
クーベンハヴンス・ユニヴェルシテット |
Ｍｕｃ１に対する癌特異的な免疫反応の産生及び癌特異的ｍｕｃ１抗体
|
|
FR2906808B1
(fr)
|
2006-10-10 |
2012-10-05 |
Univ Nantes |
Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers
|
|
WO2008101234A2
(en)
|
2007-02-16 |
2008-08-21 |
Sloan-Kettering Institute For Cancer Research |
Anti ganglioside gd3 antibodies and uses thereof
|
|
WO2008103645A2
(en)
|
2007-02-19 |
2008-08-28 |
Wisconsin Alumni Research Foundation |
Prostate cancer and melanoma antigens
|
|
CA2682093A1
(en)
|
2007-03-29 |
2008-10-09 |
Technion Research & Development Foundation Ltd. |
Antibodies, methods and kits for diagnosing and treating melanoma
|
|
WO2008127735A1
(en)
|
2007-04-13 |
2008-10-23 |
Stemline Therapeutics, Inc. |
Il3ralpha antibody conjugates and uses thereof
|
|
JP2010190572A
(ja)
|
2007-06-01 |
2010-09-02 |
Sapporo Medical Univ |
ＩＬ１３Ｒａ２に対する抗体およびこれを含む診断・治療薬
|
|
AU2008282863A1
(en)
|
2007-07-31 |
2009-02-05 |
Merck Sharp & Dohme Corp. |
IGF-1R specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
|
|
HRP20150074T1
(hr)
|
2007-10-01 |
2015-03-13 |
Bristol-Myers Squibb Company |
Humana antitijela koja se vežu za mezotelin i njihove uporabe
|
|
KR101559599B1
(ko)
|
2007-11-26 |
2015-10-12 |
바이엘 인텔렉쳐 프로퍼티 게엠베하 |
항-메소텔린 항체 및 이의 용도
|
|
AR071891A1
(es)
|
2008-05-30 |
2010-07-21 |
Imclone Llc |
Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
|
|
JP2012503203A
(ja)
|
2008-09-19 |
2012-02-02 |
ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション |
基底乳癌腫の診断および処置のためのｃｓｐｇ４に対するモノクローナル抗体
|
|
WO2010043721A1
(en)
|
2008-10-17 |
2010-04-22 |
Oryzon Genomics, S.A. |
Oxidase inhibitors and their use
|
|
US20110239315A1
(en)
|
2009-01-12 |
2011-09-29 |
Ulla Bonas |
Modular dna-binding domains and methods of use
|
|
EP2206723A1
(en)
|
2009-01-12 |
2010-07-14 |
Bonas, Ulla |
Modular DNA-binding domains
|
|
US8993808B2
(en)
|
2009-01-21 |
2015-03-31 |
Oryzon Genomics, S.A. |
Phenylcyclopropylamine derivatives and their medical use
|
|
ES2550639T3
(es)
|
2009-04-27 |
2015-11-11 |
Kyowa Hakko Kirin Co., Ltd. |
Anticuerpo anti-IL-3Ralfa para su utilización en el tratamiento de un tumor de la sangre
|
|
WO2011035941A1
(en)
|
2009-09-25 |
2011-03-31 |
Oryzon Genomics S.A. |
Lysine specific demethylase-1 inhibitors and their use
|
|
US8946296B2
(en)
|
2009-10-09 |
2015-02-03 |
Oryzon Genomics S.A. |
Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
|
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
CA3040276A1
(en)
|
2009-12-02 |
2011-06-09 |
Imaginab, Inc. |
J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
|
|
ES2573642T3
(es)
|
2009-12-23 |
2016-06-09 |
Synimmune Gmbh |
Anticuerpos anti-FLT3 y métodos de usar los mismos
|
|
CN105777907B
(zh)
|
2010-02-24 |
2020-03-17 |
伊缪诺金公司 |
叶酸受体1抗体与免疫缀合物以及其用途
|
|
US9242014B2
(en)
|
2010-06-15 |
2016-01-26 |
The Regents Of The University Of California |
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
|
|
NZ603581A
(en)
|
2010-06-19 |
2015-05-29 |
Sloan Kettering Inst Cancer |
Anti-gd2 antibodies
|
|
CA2805442C
(en)
|
2010-07-21 |
2020-05-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of an hla locus
|
|
EP2598480B1
(en)
|
2010-07-29 |
2019-04-24 |
Oryzon Genomics, S.A. |
Cyclopropylamine derivatives useful as lsd1 inhibitors
|
|
EP2614143B1
(en)
|
2010-09-08 |
2018-11-07 |
Baylor College Of Medicine |
Immunotherapy of non-small lung cancer using genetically engineered gd2-specific t cells
|
|
WO2012034116A2
(en)
|
2010-09-10 |
2012-03-15 |
The Johns Hopkins University |
Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
|
|
WO2012071469A2
(en)
|
2010-11-23 |
2012-05-31 |
Nevada Cancer Institute |
Histone demethylase inhibitors and uses thereof for treatment o f cancer
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
|
US20140163041A1
(en)
*
|
2011-02-08 |
2014-06-12 |
Oryzon Genomics S.A. |
Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders
|
|
MX347913B
(es)
|
2011-03-25 |
2017-05-17 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Ciclopropilaminas como inhibidores de desmetilasa 1 especifica de lisina.
|
|
ES2785081T3
(es)
|
2011-04-01 |
2020-10-05 |
Memorial Sloan Kettering Cancer Center |
Anticuerpos biespecíficos similares a receptores de células T específicos para un péptido de WT1 presentado por HLA-A2
|
|
EP3459560B1
(en)
|
2011-04-08 |
2021-02-24 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
|
|
AR086044A1
(es)
|
2011-05-12 |
2013-11-13 |
Imclone Llc |
Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
|
|
EP2714737A1
(en)
|
2011-05-27 |
2014-04-09 |
Glaxo Group Limited |
Bcma (cd269/tnfrsf17) -binding proteins
|
|
EP3692794A1
(en)
|
2011-09-16 |
2020-08-12 |
Baylor College of Medicine |
Targeting the tumor microenvironment using manipulated nkt cells
|
|
KR20140060541A
(ko)
|
2011-09-16 |
2014-05-20 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
암을 치료하기 위한 rna 조작된 t 세포
|
|
DE102011114180A1
(de)
|
2011-09-22 |
2013-03-28 |
Weber Maschinenbau Gmbh Breidenbach |
Vorrichtung zum Aufschneiden von einem Lebensmittelprodukt und Vorrichtung mit einem Roboter
|
|
FR2980528B1
(fr)
|
2011-09-22 |
2013-08-30 |
IFP Energies Nouvelles |
Procede de controle de la combustion d'un moteur a combustion interne a injection directe d'essence, notamment a allumage commande
|
|
AU2012324803B9
(en)
|
2011-10-20 |
2017-08-24 |
Oryzon Genomics, S.A. |
(hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
|
|
US9469597B2
(en)
|
2011-10-20 |
2016-10-18 |
Oryzon Genomics S.A. |
(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
|
|
ITMO20110270A1
(it)
|
2011-10-25 |
2013-04-26 |
Sara Caldrer |
Una cellula effettrice modificata per il trattamento di neoplasie esprimenti il disialonganglioside gd2
|
|
US9272002B2
(en)
|
2011-10-28 |
2016-03-01 |
The Trustees Of The University Of Pennsylvania |
Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
|
WO2013074916A1
(en)
|
2011-11-18 |
2013-05-23 |
Board Of Regents, The University Of Texas System |
Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
|
|
US9439768B2
(en)
|
2011-12-08 |
2016-09-13 |
Imds Llc |
Glenoid vault fixation
|
|
EP2814846B1
(en)
|
2012-02-13 |
2020-01-08 |
Seattle Children's Hospital d/b/a Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
|
CA3285826A1
(en)
|
2012-02-22 |
2026-03-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
|
|
CA2868121C
(en)
|
2012-03-23 |
2021-06-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
|
KR20150006000A
(ko)
|
2012-05-01 |
2015-01-15 |
제넨테크, 인크. |
항-pmel17 항체 및 면역접합체
|
|
EP2850106B1
(en)
|
2012-05-18 |
2022-03-23 |
Aptevo Research and Development LLC |
Bispecific scfv immunofusion (bif) binding to cd123 and cd3
|
|
ES2728782T3
(es)
|
2012-05-25 |
2019-10-28 |
Univ California |
Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
|
|
WO2013192294A1
(en)
|
2012-06-20 |
2013-12-27 |
Boston 3T Biotechnologies, Inc. |
Cellular therapies for treating and preventing cancers and other immune system disorders
|
|
CN116622704A
(zh)
|
2012-07-25 |
2023-08-22 |
布罗德研究所有限公司 |
可诱导的dna结合蛋白和基因组干扰工具及其应用
|
|
LT2884999T
(lt)
|
2012-08-20 |
2021-04-12 |
Fred Hutchinson Cancer Research Center |
Ląstelinės imunoterapijos būdas ir kompozicijos
|
|
US10316289B2
(en)
*
|
2012-09-06 |
2019-06-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of producing T memory stem cell populations
|
|
WO2014055442A2
(en)
|
2012-10-01 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
|
US10117896B2
(en)
|
2012-10-05 |
2018-11-06 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
|
EP3064585B1
(en)
|
2012-12-12 |
2020-02-05 |
The Broad Institute, Inc. |
Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
|
|
SG10201707569YA
(en)
|
2012-12-12 |
2017-10-30 |
Broad Inst Inc |
Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
|
|
PT2931898E
(pt)
|
2012-12-12 |
2016-06-16 |
Harvard College |
Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais
|
|
WO2014093709A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
|
EP2931899A1
(en)
|
2012-12-12 |
2015-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
|
|
CN105209621B
(zh)
|
2012-12-12 |
2021-05-25 |
布罗德研究所有限公司 |
对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
|
|
MX380562B
(es)
|
2012-12-12 |
2025-03-12 |
Broad Inst Inc |
Modificaciones de sistemas, métodos y composiciones guía optimizadas para la manipulación de secuencias.
|
|
KR102955556B1
(ko)
|
2012-12-12 |
2026-04-22 |
더 브로드 인스티튜트, 인코퍼레이티드 |
서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물
|
|
WO2014093694A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
SG11201505896YA
(en)
|
2013-02-20 |
2015-09-29 |
Novartis Ag |
Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
|
|
WO2014130635A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
|
|
US20160046718A1
(en)
|
2013-03-14 |
2016-02-18 |
Csl Limited |
Agents that neutralize il-3 signalling and uses thereof
|
|
WO2014138805A1
(en)
|
2013-03-14 |
2014-09-18 |
Csl Limited |
Anti il-3r alpha agents and uses thereof
|
|
US9657105B2
(en)
|
2013-03-15 |
2017-05-23 |
City Of Hope |
CD123-specific chimeric antigen receptor redirected T cells and methods of their use
|
|
US11332719B2
(en)
|
2013-03-15 |
2022-05-17 |
The Broad Institute, Inc. |
Recombinant virus and preparations thereof
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
EP3789487A1
(en)
*
|
2013-04-03 |
2021-03-10 |
Memorial Sloan Kettering Cancer Center |
Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
|
|
EP3004339B1
(en)
|
2013-05-29 |
2021-07-07 |
Cellectis |
New compact scaffold of cas9 in the type ii crispr system
|
|
WO2014204725A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
|
|
KR20250012194A
(ko)
|
2013-06-17 |
2025-01-23 |
더 브로드 인스티튜트, 인코퍼레이티드 |
바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용
|
|
SG11201510327TA
(en)
|
2013-06-17 |
2016-01-28 |
Broad Inst Inc |
Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
|
|
WO2014204723A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Oncogenic models based on delivery and use of the crispr-cas systems, vectors and compositions
|
|
JP6738728B2
(ja)
|
2013-06-17 |
2020-08-19 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
肝臓ターゲティングおよび治療のためのＣＲＩＳＰＲ−Ｃａｓ系、ベクターおよび組成物の送達および使用
|
|
EP3011033B1
(en)
|
2013-06-17 |
2020-02-19 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
|
ES2777217T3
(es)
|
2013-06-17 |
2020-08-04 |
Broad Inst Inc |
Suministro, modificación y optimización de sistemas de guía en tándem, métodos y composiciones para la manipulación de secuencias
|
|
CN105555784B
(zh)
|
2013-06-19 |
2019-03-15 |
犹他大学研究基金会 |
作为组蛋白去甲基化酶抑制剂的被取代的(e)-n’-(1-苯亚乙基)苯甲酰肼类似物
|
|
EP3027755B1
(en)
*
|
2013-08-02 |
2019-10-09 |
The Regents of The University of California |
Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
|
|
WO2015031564A2
(en)
|
2013-08-30 |
2015-03-05 |
University Of Utah |
Substituted-1h-benzo[d]imidazole series compounds as lysine-specfic demethylase 1 (lsd1) inhibitors
|
|
WO2015048577A2
(en)
|
2013-09-27 |
2015-04-02 |
Editas Medicine, Inc. |
Crispr-related methods and compositions
|
|
ES2918501T3
(es)
|
2013-12-19 |
2022-07-18 |
Novartis Ag |
Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
|
|
EP3392244A1
(en)
|
2014-02-13 |
2018-10-24 |
Incyte Corporation |
Cyclopropylamines as lsd1 inhibitors
|
|
LT3105218T
(lt)
|
2014-02-13 |
2019-12-10 |
Incyte Corp |
Ciklopropilaminai kaip lsd1 inhibitoriai
|
|
US9527835B2
(en)
|
2014-02-13 |
2016-12-27 |
Incyte Corporation |
Cyclopropylamines as LSD1 inhibitors
|
|
CN122399016A
(zh)
|
2014-03-15 |
2026-07-17 |
诺华股份有限公司 |
使用嵌合抗原受体治疗癌症
|
|
KR20160146747A
(ko)
*
|
2014-03-31 |
2016-12-21 |
제넨테크, 인크. |
항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
|
|
SG10202109752XA
(en)
|
2014-04-07 |
2021-10-28 |
Novartis Ag |
Treatment of cancer using anti-cd19 chimeric antigen receptor
|
|
NZ725262A
(en)
|
2014-04-11 |
2023-01-27 |
Takeda Pharmaceuticals Co |
Cyclopropanamine compound and use thereof
|
|
MX375102B
(es)
*
|
2014-05-30 |
2025-03-06 |
Ieo St Europeo Di Oncologia S R L |
Compuestos de ciclopropilamina como inhibidores de histona demetilasa
|
|
JP6831777B2
(ja)
|
2014-07-21 |
2021-02-17 |
ノバルティス アーゲー |
Ｃｄ３３キメラ抗原受容体を使用する癌の処置
|
|
AU2015292744C1
(en)
|
2014-07-21 |
2021-01-21 |
Novartis Ag |
Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
|
|
BR112017000939A2
(pt)
|
2014-07-21 |
2017-11-14 |
Novartis Ag |
tratamento de câncer usando um receptor antigênico quimérico de cll-1
|
|
EP3172231B1
(en)
|
2014-07-24 |
2021-05-05 |
Bluebird Bio, Inc. |
Bcma chimeric antigen receptors
|
|
EP3180359A1
(en)
|
2014-08-14 |
2017-06-21 |
Novartis AG |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
|
EP3712171A1
(en)
|
2014-08-19 |
2020-09-23 |
Novartis AG |
Treatment of cancer using a cd123 chimeric antigen receptor
|
|
JP6980534B2
(ja)
*
|
2015-06-25 |
2021-12-15 |
ザ チルドレンズ メディカル センター コーポレーション |
造血幹細胞の増大、富化、および維持に関する方法および組成物
|
|
WO2017161001A1
(en)
*
|
2016-03-15 |
2017-09-21 |
Children's Medical Center Corporation |
Methods and compositions relating to hematopoietic stem cell expansion
|
|
WO2018059549A1
(en)
*
|
2016-09-30 |
2018-04-05 |
Novartis Ag |
Immune effector cell therapies with enhanced efficacy
|